IGF::OT::IGF NExT Project IDH1_2-Pyridinone TO#2 Characterization of Tox of Potential Anticancer Compounds Following Multiple Dose Admin to Rats, 1/26/17-6/30/18, Pre-clin Tox Study of Drug Dev for Ca

IGF::OT::IGF NExT 项目 IDH1_2-吡啶酮 TO

• 批准号: 9578256
• 负责人: Maryellen Lynch
• 金额: $ 25.6万
• 依托单位: BATTELLE MEMORIAL INSTITU
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-01-26 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9578256
• 关键词: 2-hydroxypyridine; Award; Biological; Biological Availability; Body Weight; Cardiovascular system; Clinical; Clinical Chemistry; Contracts; Data; Development; Dose; Drug Kinetics; Evaluation; Hematology; Histopathology; Investigation; Liquid substance; Malignant Neoplasms; Measures; Metabolic Clearance Rate; Methodology; Oral; Organ; Pharmaceutical Preparations; Plasma; Process; Rat-1; Reporting; Rodent; Specific qualifier value; Testing; Time; Tissues; Toxic effect; acute toxicity; anti-cancer therapeutic; anticancer activity; drug candidate; neurotoxicity; research clinical testing

The test agent is being considered for development as an anticancer therapeutic. The objective of this task was to characterize the target organ toxicities of an investigative agent that might move forward to clinical testing for anticancer activity. The information obtained from this investigation was used to identify drugs with the potential to treat cancer.

正在考虑将供试药物开发为抗癌治疗药物。 该任务的目的是表征研究药物的靶器官毒性，从而可能推进抗癌活性的临床试验。 从这项研究中获得的信息被用于确定具有治疗癌症潜力的药物。